About
Technology
Issues
FAQ
Links
Official Page
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.